572922-91-9

Basic information

• Product Name: 1-Pyrrolidinecarboxylic acid, 2-[[[(1R,2S)-2-ethenyl-1-(methoxycarbonyl)cyclopropyl]amino]carbonyl]- 4-hydroxy-, 1,1-dimethylethyl ester, (2S,4S)-
• CAS NO: 572922-91-9
• Molecular Formula: C17H26N2O6
• Molecular Weight: 354.403
• Mol File: 572922-91-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-Pyrrolidinecarboxylic acid, 2-[[[(1R,2S)-2-ethenyl-1-(methoxycarbonyl)cyclopropyl]amino]carbonyl]- 4-hydroxy-, 1,1-dimethylethyl ester, (2S,4S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxylic acid, 2-[[[(1R,2S)-2-ethenyl-1-(methoxycarbonyl)cyclopropyl]amino]carbonyl]- 4-hydroxy-, 1,1-dimethylethyl ester, (2S,4S)-(572922-91-9)
• EPA Substance Registry System: 1-Pyrrolidinecarboxylic acid, 2-[[[(1R,2S)-2-ethenyl-1-(methoxycarbonyl)cyclopropyl]amino]carbonyl]- 4-hydroxy-, 1,1-dimethylethyl ester, (2S,4S)-(572922-91-9)

Safety Data

• Hazardous Substances Data: 572922-91-9(Hazardous Substances Data)

Usage

Molecular weight

295.31 g/mol The mass of one mole of the compound, calculated from its molecular formula.

Functional groups

Carboxyl, Ester, Amino, and Hydroxyl The specific functional groups present in the compound that determine its chemical reactivity and properties.

Stereochemistry

(1R,2S) and (2S,4S) The specific spatial arrangement of the atoms in the molecule, which can affect its biological activity and interactions with other molecules.

Bityrosine derivative

A rare compound found in proteins and peptides The compound is derived from bityrosine, an uncommon amino acid that is formed through the oxidation of tyrosine.

Involvement in oxidative stress and inflammation

The compound is thought to be involved in these processes in the body, which can have implications for various diseases and conditions.

Pharmaceutical research and development

The compound has potential implications for pharmaceutical research, particularly in the study of protein structure and function, as it is a derivative of an amino acid that can affect these properties.

Upstream product

• 862273-27-6 (1R,2S)-1-amino-2-vinylcyclopropane carboxylic acid methyl ester tosylate salt 
• 87691-27-8 N-tert-butoxycarbonyl-L-cis-4-hydroxyproline 
• 681260-04-8 (1R,2S)-1-amino-2-vinyl-cyclopropyl carboxylic acid methyl ester 

Downstream Products

• 1098199-68-8 C₁₈H₂₁BrN₂O₆S*ClH 
• 801282-60-0 C₂₃H₂₉BrN₂O₈S 
• 572922-90-8 (2S,4S)-2-((1R,2S)-1-Methoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-4-(4-nitro-benzoyloxy)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 300832-84-2 ciluprevir 
• 300831-46-3 methyl (2S,6S,12Z,13aS,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-2-hydroxy-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxylate 

Relevant articles and documents

MACROCYCLIC INHIBITORS OF HEPATITIS C PROTEASE

The invention provides macrocyclic compounds inhibitory to the Hepatitis C viral protease, compositions and combinations including the compounds, methods of treatment of conditions wherein inhibition of the Hepatitis C viral protease is medically indicated, and methods of treatment of a Hepatitis C viral infection in a human patient.

HEPATITIS C INHIBITOR COMPOUNDS

Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.